{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T00:02:49Z","timestamp":1770422569397,"version":"3.49.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"1181","license":[{"start":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T00:00:00Z","timestamp":1701820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Taiwan Ministry of Science and Technology","doi-asserted-by":"crossref","award":["MOST 111-2314-B-038-103"],"award-info":[{"award-number":["MOST 111-2314-B-038-103"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004663","name":"Taiwan Ministry of Science and Technology","doi-asserted-by":"crossref","award":["107-2314-B-038-019-MY3"],"award-info":[{"award-number":["107-2314-B-038-019-MY3"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004663","name":"Taiwan Ministry of Science and Technology","doi-asserted-by":"crossref","award":["NSTC 111-2218-E-008-009"],"award-info":[{"award-number":["NSTC 111-2218-E-008-009"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Higher Education Sprout Project by the Ministry of Education","award":["DP2-111-21121-01-O-13"],"award-info":[{"award-number":["DP2-111-21121-01-O-13"]}]},{"DOI":"10.13039\/501100010613","name":"Taipei Medical University Hospital","doi-asserted-by":"publisher","award":["112TMU-TMUH-14"],"award-info":[{"award-number":["112TMU-TMUH-14"]}],"id":[{"id":"10.13039\/501100010613","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010613","name":"Taipei Medical University Hospital","doi-asserted-by":"publisher","award":["109TMU-TMUH-22"],"award-info":[{"award-number":["109TMU-TMUH-22"]}],"id":[{"id":"10.13039\/501100010613","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,2,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Contrast-induced nephropathy has become increasingly prevalent as the age and prevalence of comorbidities in the general population have increased. Most cases of contrast-induced nephropathy are reversible; however, some may progress to acute kidney disease, and subsequently, to chronic kidney disease. Sodium\u2013glucose cotransporter 2 inhibitors (SGLT2i) are known for their renoprotective effects. However, whether the use of these inhibitors affects the risk of contrast-induced kidney injury remains unclear.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Data were collected from the Taipei Medical University Clinical Research Database. We included patients with diabetes who had contrast exposure between 2016 and 2020 because of computed tomography or coronary angiography. The primary outcome was the risk of a major adverse kidney event (MAKE), which encompassed acute kidney disease, chronic kidney disease progression, and the need for renal replacement therapy. Overlap weighting was performed to reduce the effects of potential confounders.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>This study included 12\u2009421 patients, who were divided into two groups: SGLT2i users (n\u2009=\u2009920) and nonusers (n\u2009=\u200911\u2009501). The follow-up period after contrast exposure was 6\u00a0months. The risk of a MAKE was lower in SGLT2i users than in nonusers (incidence, 36.9 vs. 49.9 per 1000 person-months, respectively; P\u2009=\u2009.0011). Furthermore, the incidence of acute kidney disease or chronic kidney disease progression was significantly lower in the SGLT2i users than in nonusers. However, no significant between-group difference was noted in the incidence of other MAKEs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>SGLT2i may be safely used in diabetic patients needing contrast exposure. The risk of a MAKE may be lower in SGLT2i users than in nonusers.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/postmj\/qgad118","type":"journal-article","created":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T05:50:44Z","timestamp":1701928244000},"page":"142-150","source":"Crossref","is-referenced-by-count":2,"title":["Renal outcomes after contrast exposure in patients with diabetes who use sodium\u2013glucose cotransporter 2 inhibitors"],"prefix":"10.1093","volume":"100","author":[{"given":"Chih-Wei","family":"Chen","sequence":"first","affiliation":[{"name":"Division of Cardiology , Department of Internal Medicine, School of Medicine, , Taipei, 110 , Taiwan"},{"name":"College of Medicine, Taipei Medical University , Department of Internal Medicine, School of Medicine, , Taipei, 110 , Taiwan"},{"name":"Division of Cardiology , Department of Internal Medicine and Cardiovascular Research Center, , Taipei, 110 , Taiwan"},{"name":"Taipei Medical University Hospital , Department of Internal Medicine and Cardiovascular Research Center, , Taipei, 110 , Taiwan"},{"name":"Taipei Heart Institute, Taipei Medical University , Taipei, 110 , Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fu-You","family":"Su","sequence":"additional","affiliation":[{"name":"Division of Cardiology , Department of Internal Medicine, , Taipei, 111 , Taiwan"},{"name":"Shin Kong Wu Ho-Su Memorial Hospital , Department of Internal Medicine, , Taipei, 111 , Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping-Ping","family":"Wang","sequence":"additional","affiliation":[{"name":"Division of Cardiology , Department of Internal Medicine and Cardiovascular Research Center, , Taipei, 110 , Taiwan"},{"name":"Taipei Medical University Hospital , Department of Internal Medicine and Cardiovascular Research Center, , Taipei, 110 , Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8945-3513","authenticated-orcid":false,"given":"Ming-Tsang","family":"Chuang","sequence":"additional","affiliation":[{"name":"Research Information Section, Office of Information Technology, Taipei Medical University , Taipei, 110 , Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3599-7758","authenticated-orcid":false,"given":"Yi-Cheng","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Taipei Medical University Hospital , Taipei, 110 , Taiwan"},{"name":"School of Pharmacy, College of Pharmacy, Taipei Medical University , Taipei, 110 , Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chih-Chin","family":"Kao","sequence":"additional","affiliation":[{"name":"Division of Nephrology , Department of Internal Medicine, School of Medicine, , Taipei, 110 , Taiwan"},{"name":"College of Medicine, Taipei Medical University , Department of Internal Medicine, School of Medicine, , Taipei, 110 , Taiwan"},{"name":"Division of Nephrology , Department of Internal Medicine, , Taipei, 110 , Taiwan"},{"name":"Taipei Medical University Hospital , Department of Internal Medicine, , Taipei, 110 , Taiwan"},{"name":"TMU Research Center of Urology and Kidney, Taipei Medical University , Taipei, 110 , Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Yao","family":"Huang","sequence":"additional","affiliation":[{"name":"Division of Cardiology , Department of Internal Medicine, School of Medicine, , Taipei, 110 , Taiwan"},{"name":"College of Medicine, Taipei Medical University , Department of Internal Medicine, School of Medicine, , Taipei, 110 , Taiwan"},{"name":"Division of Cardiology , Department of Internal Medicine and Cardiovascular Research Center, , Taipei, 110 , Taiwan"},{"name":"Taipei Medical University Hospital , Department of Internal Medicine and Cardiovascular Research Center, , Taipei, 110 , Taiwan"},{"name":"Taipei Heart Institute, Taipei Medical University , Taipei, 110 , Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,12,6]]},"reference":[{"key":"2024021913552187200_ref1","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/S0002-9343(97)00150-2","article-title":"Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality","volume":"103","author":"McCullough","year":"1997","journal-title":"Am J Med"},{"key":"2024021913552187200_ref2","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1016\/j.jacc.2004.07.043","article-title":"Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction","volume":"44","author":"Marenzi","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"2024021913552187200_ref3","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1148\/radiol.12121460","article-title":"Frequency of acute kidney injury following intravenous contrast medium administration: a systematic review and meta-analysis","volume":"267","author":"McDonald","year":"2013","journal-title":"Radiology"},{"key":"2024021913552187200_ref4","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1186\/s12967-020-02574-8","article-title":"Contrast-induced nephropathy and oxidative stress: mechanistic insights for better interventional approaches","volume":"18","author":"Kusirisin","year":"2020","journal-title":"J Transl Med"},{"key":"2024021913552187200_ref5","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2214\/ajr.157.1.2048540","article-title":"Radiocontrast-associated renal dysfunction: a comparison of lower-osmolality and conventional high-osmolality contrast media","volume":"157","author":"Lautin","year":"1991","journal-title":"AJR Am J Roentgenol"},{"key":"2024021913552187200_ref6","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1161\/01.CIR.0000016043.87291.33","article-title":"Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention","volume":"105","author":"Rihal","year":"2002","journal-title":"Circulation"},{"key":"2024021913552187200_ref7","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"2024021913552187200_ref8","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"2024021913552187200_ref9","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with Empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"2024021913552187200_ref10","first-page":"1436","article-title":"Dapagliflozin in patients with chronic kidney disease","volume-title":"N Engl J Med","author":"Heerspink","year":"2020"},{"key":"2024021913552187200_ref11","doi-asserted-by":"crossref","first-page":"e148","DOI":"10.2337\/dc22-0921","article-title":"Activation of the tubulo-glomerular feedback by SGLT2 inhibitors in patients with type 2 diabetes and advanced chronic kidney disease: toward the end of a myth?","volume":"45","author":"Gerard","year":"2022","journal-title":"Diabetes Care"},{"key":"2024021913552187200_ref12","doi-asserted-by":"crossref","first-page":"110766","DOI":"10.1016\/j.diabres.2023.110766","article-title":"Impact of SGLT2-inhibitors on contrast-induced acute kidney injury in diabetic patients with acute myocardial infarction with and without chronic kidney disease: insight from SGLT2-I AMI PROTECT registry","volume":"202","author":"Paolisso","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"key":"2024021913552187200_ref13","doi-asserted-by":"crossref","first-page":"106659","DOI":"10.1016\/j.phrs.2023.106659","article-title":"Dapagliflozin protects the kidney in a non-diabetic model of cardiorenal syndrome","volume":"188","author":"Urbanek","year":"2023","journal-title":"Pharmacol Res"},{"key":"2024021913552187200_ref14","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/s41569-020-0406-8","article-title":"SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control","volume":"17","author":"Cowie","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"2024021913552187200_ref15","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s13098-023-01107-9","article-title":"The safety of SGLT-2 inhibitors in diabetic patients submitted to elective percutaneous coronary intervention regarding kidney function: SAFE-PCI pilot study","volume":"15","author":"Feitosa","year":"2023","journal-title":"Diabetol Metab Syndr"},{"key":"2024021913552187200_ref16","article-title":"Adverse outcomes after major surgeries in patients with diabetes: a Multicenter matched study","volume":"8","author":"Lin","year":"2019","journal-title":"J Clin Med"},{"key":"2024021913552187200_ref17","doi-asserted-by":"crossref","DOI":"10.1136\/postgradmedj-2021-140341","article-title":"Effects of osteoporosis medications on bone fracture in patients with chronic kidney disease","volume":"99","author":"Kao","year":"2023","journal-title":"Postgrad Med J"},{"key":"2024021913552187200_ref18","doi-asserted-by":"crossref","first-page":"c179","DOI":"10.1159\/000339789","article-title":"KDIGO clinical practice guidelines for acute kidney injury","volume":"120","author":"Khwaja","year":"2012","journal-title":"Nephron Clin Pract"},{"key":"2024021913552187200_ref19","first-page":"250","article-title":"Addressing extreme propensity scores via the overlap weights","volume":"188","author":"Li","year":"2019","journal-title":"Am J Epidemiol"},{"key":"2024021913552187200_ref20","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/j.jacc.2016.05.099","article-title":"Contrast-induced acute kidney injury","volume":"68","author":"McCullough","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2024021913552187200_ref21","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1161\/CIRCULATIONAHA.115.014672","article-title":"Contrast-induced nephropathy","volume":"132","author":"Wichmann","year":"2015","journal-title":"Circulation"},{"key":"2024021913552187200_ref22","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1056\/NEJM199411243312104","article-title":"Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents","volume":"331","author":"Solomon","year":"1994","journal-title":"N Engl J Med"},{"key":"2024021913552187200_ref23","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/j.amjcard.2015.02.004","article-title":"Role of hydration in contrast-induced nephropathy in patients who underwent primary percutaneous coronary intervention","volume":"115","author":"Jurado-Roman","year":"2015","journal-title":"Am J Cardiol"},{"key":"2024021913552187200_ref24","doi-asserted-by":"crossref","first-page":"776","DOI":"10.5301\/jn.5000059","article-title":"ACE inhibitor or angiotensin II receptor blocker use is a risk factor for contrast-induced nephropathy","volume":"25","author":"Umruddin","year":"2012","journal-title":"J Nephrol"},{"key":"2024021913552187200_ref25","doi-asserted-by":"crossref","first-page":"423848","DOI":"10.1155\/2014\/423848","article-title":"ACE-I\/ARB therapy prior to contrast exposure: what should the clinician do?","volume":"2014","author":"Kalyesubula","year":"2014","journal-title":"Biomed Res Int"},{"key":"2024021913552187200_ref26","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.2215\/CJN.02480221","article-title":"Clinical implications of an acute dip in eGFR after SGLT2 inhibitor initiation","volume":"16","author":"Heerspink","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"2024021913552187200_ref27","doi-asserted-by":"crossref","first-page":"513","DOI":"10.7326\/0003-4819-115-7-513","article-title":"Reversible renal insufficiency due to angiotensin converting enzyme inhibitors in hypertensive nephrosclerosis","volume":"115","author":"Toto","year":"1991","journal-title":"Ann Intern Med"},{"key":"2024021913552187200_ref28","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1053\/j.ajkd.2012.04.017","article-title":"The effect of renin-angiotensin-aldosterone system blockade on contrast-induced acute kidney injury: a propensity-matched study","volume":"60","author":"Rim","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"2024021913552187200_ref29","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ahj.2015.04.019","article-title":"Effects of withdrawing vs continuing renin-angiotensin blockers on incidence of acute kidney injury in patients with renal insufficiency undergoing cardiac catheterization: results from the angiotensin converting enzyme inhibitor\/angiotensin receptor blocker and contrast induced nephropathy in patients receiving cardiac catheterization (CAPTAIN) trial","volume":"170","author":"Bainey","year":"2015","journal-title":"Am Heart J"},{"key":"2024021913552187200_ref30","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.023811","article-title":"National Trends in use of sodium-glucose Cotransporter-2 inhibitors and glucagon-like Peptide-1 receptor agonists by cardiologists and other specialties, 2015 to 2020","volume":"11","author":"Adhikari","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"2024021913552187200_ref31","doi-asserted-by":"crossref","first-page":"918167","DOI":"10.3389\/fcvm.2022.918167","article-title":"Contrast-induced acute kidney injury in patients on SGLT2 inhibitors undergoing percutaneous coronary interventions: a propensity-matched analysis","volume":"9","author":"Hua","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"2024021913552187200_ref32","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1161\/CIRCULATIONAHA.111.085290","article-title":"Persistent renal damage after contrast-induced acute kidney injury: incidence, evolution, risk factors, and prognosis","volume":"125","author":"Maioli","year":"2012","journal-title":"Circulation"},{"key":"2024021913552187200_ref33","doi-asserted-by":"crossref","DOI":"10.3390\/medicina59030505","article-title":"The effect of SGLT2 inhibitors on the development of contrast-induced nephropathy in diabetic patients with non-ST segment elevation myocardial infarction","volume":"59","author":"Ozkan","year":"2023","journal-title":"Medicina"},{"key":"2024021913552187200_ref34","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12933-022-01476-x","article-title":"Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis","volume":"21","author":"Kaze","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"2024021913552187200_ref35","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1053\/j.ajkd.2021.09.015","article-title":"SGLT2 inhibitors and the risk of acute kidney injury in older adults with type 2 diabetes","volume":"79","author":"Zhuo","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"2024021913552187200_ref36","doi-asserted-by":"crossref","first-page":"70","DOI":"10.2215\/CJN.11220720","article-title":"Network meta-analysis of novel glucose-lowering drugs on risk of acute kidney injury","volume":"16","author":"Zhao","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"2024021913552187200_ref37","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1007\/s00125-021-05407-5","article-title":"Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial","volume":"64","author":"Cherney","year":"2021","journal-title":"Diabetologia"},{"key":"2024021913552187200_ref38","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.kint.2020.10.031","article-title":"Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial","volume":"99","author":"Kraus","year":"2021","journal-title":"Kidney Int"},{"key":"2024021913552187200_ref39","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.kint.2020.10.042","article-title":"Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice","volume":"99","author":"Oshima","year":"2021","journal-title":"Kidney Int"},{"key":"2024021913552187200_ref40","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.cmet.2021.02.016","article-title":"A kidney perspective on the mechanism of action of sodium glucose co-transporter 2 inhibitors","volume":"33","author":"Sen","year":"2021","journal-title":"Cell Metab"}],"container-title":["Postgraduate Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/100\/1181\/142\/56682907\/qgad118.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/100\/1181\/142\/56682907\/qgad118.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T14:12:11Z","timestamp":1708351931000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/pmj\/article\/100\/1181\/142\/7458906"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,6]]},"references-count":40,"journal-issue":{"issue":"1181","published-online":{"date-parts":[[2023,12,6]]},"published-print":{"date-parts":[[2024,2,15]]}},"URL":"https:\/\/doi.org\/10.1093\/postmj\/qgad118","relation":{},"ISSN":["0032-5473","1469-0756"],"issn-type":[{"value":"0032-5473","type":"print"},{"value":"1469-0756","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,3]]},"published":{"date-parts":[[2023,12,6]]}}}